Peak Pharmaceuticals Inc. ehemals Cannabis Therapy Corp. $CTCO - 500 Beiträge pro Seite

[clickclickcash]

Heute entdeckt, könnte interessant werden:

Peak Pharmaceuticals Inc. ehemals Cannabis Therapy Corp.

WKN A114DU | ISIN US13764J1079 | OTC: CTCO

Handelbar an der Börse Stuttgart und Nasdaq OTC

Anzahl der Aktien: 78.364.000

Marktkapitalisierung: 12,93 Mio. €

Peak Pharmaceuticals, Inc., through its subsidiary, Peak BioPharma Corp., engages in the development, manufacture, and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets. The company is involved in the production and sale of hemp based animal health products based on Canna-Pet license agreement. It intends to develop over-the-counter, ultra-low and tetrahydrocannabinoil-free, and hemp-based products for the prevention and alleviation of inflammatory and autoimmune diseases. The company was formerly known as Cannabis Therapy Corporation and changed its name to Peak.

About Peak Pharmaceuticals, Inc.
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based nutraceutical and supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of medicinal hemp and cannabinoid products.

About Canna-Pet™ Products for Pet Health
Canna-Pet™ is one of the first cannabinoid (CBD) product designed specifically for cats and dogs. Available over-the-counter, Canna-Pet™ produces veterinarian recommended, legal, cannabidiol (CBD) products for animals, made from industrial hemp and manufactured in the USA. Canna-Pet® products contain not only CBD, but carefully controlled ratios of other cannabinoids and terpenes which make the products uniquely effective. Now available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc.

www.peakpharma.com

[clickclickcash]

Cannabis Therapy Corp. and Canna-Pet, LLC Enter Exclusive Licensing Agreement

August 5, 2014

Company Launches Into Animal Health Sector Aiming to Boost Proven Brand to New Levels of Success

BOULDER, CO–Peak Pharma Inc.. (OTCQB: CTCO) (the “Company”), a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, ultra-low THC, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to announce the execution of a definitive licensing agreement with Canna-Pet, LLC of Seattle, WA.

Under the terms of the agreement, Peak Pharma Inc.., in exchange for sales royalties, now has an exclusive worldwide license and rights to the technology and products currently developed by Canna-Pet, LLC and the possibility for co-development of future animal health products. The agreement covers production and sale of animal health and pet products made from hemp, a low-THC cannabis plant and results in the transfer of future revenues, brand identity, management expertise, goodwill, sales materials and customer base from Canna-Pet, LLC to Peak Pharma Inc..

The animal health sector encompasses livestock and working animals as well as pets. Whether an animal has high intrinsic value or is a valued family member, quality assured, pharmaceutical grade products are in great demand and significantly aid in the creation of trusted, high value brands. According to a State of the American Pet Survey, one of the greatest challenges of pet ownership is maintaining pets’ health. 41% of pet owners have considered or tried various alternative therapies, including nutritional supplements (29%), herbal remedies (7%) and homeopathy (4%).

Canna-Pet products were developed in a collaboration between Doctors of Veterinary Medicine in six states and an MIT entrepreneur. The company is the culmination of twenty years of research and development in cannabinoid therapies for animals. Canna-Pet, LLC currently leads the industry with veterinarian recommended, legal, over the counter Cannabidiol (CBD) products for pets made in the USA from industrial hemp. For more information please visit: www.canna-pet.com.

“We are thrilled to make this important announcement today,” comments Dan Goldfarb, President of Canna-Pet, LLC. “The recession-resistant animal health products industry is projected to reach $12 billion in the USA alone by 2016 and to-date we have made great progress in pioneering an industry segment that we believe is poised to explode globally. Twenty years of animal research mirrors many current human studies indicating that CBD therapies can assist with inflammation, anxiety, compromised immune systems, digestive issues, nausea, chronic pain and seizures. Our relationship with Peak Pharma Inc.. complements their ongoing human health science R&D efforts while rapidly elevating our core science competency, operational and financial planning well beyond what we have developed to-date.”

Peak Pharma Inc.. President and CEO Dr. Soren Mogelsvang states, “We set out to become cash flow positive as quickly as possible and this fit comes with near term revenues and the extraordinary upside that the Canna-Pet business almost seamlessly integrates with our ongoing efforts for developing human therapies. Providing hemp-based, veterinary-grade extracts to the rapidly growing but undervalued over the counter animal health market is simply the first of several revenue streams currently available to us in the medicinal cannabis marketplace. Our commitment to commercialization of an entire suite of products just got a huge and important kickstart, which will aid greatly in our efforts to seek out additional sources of capital while operationally fine tuning our development, sales and marketing efforts exponentially.”

Quelle: http://peakpharma.com/cannabis-therapy-corp-canna-pet-llc-en…

[clickclickcash]

Cannabis Therapy Corp. Announces Revenue Milestone With Launch of Updated Canna-Pet™ Website

October 22, 2014

New Look Website Spurs Product Sales for Leading Hemp-Based Pet Health Affiliate

BOULDER, CO–Peak Pharma Inc.. (OTCQB: CTCO) (the “Company”), a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, ultra-low THC, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is extremely pleased to announce the launch of its all-new Canna-Pet™ commercial website (www.canna-pet.com).

Moving quickly to maximize the current and potential interest in cannabidiol (CBD) based pet supplements, Peak Pharma Inc.. has quickly seized on existing customer momentum as the basis for the redevelopment of the Canna-Pet™ online sales portal. The website was redeveloped in an effort to improve its functionality and customer support, and to integrate proven digital marketing strategies as a means of seeking to boost sales and resulting revenues.

Sales resulting from launch of the website will result in the immediate receipt of revenues from operations for Peak Pharma Inc., which is the exclusive worldwide license holder for sales of Canna-Pet™ products. Revenues will be reported as part of the Company’s ongoing regulatory disclosure in its Q1 2015 quarterly earnings report.

Peak Pharma Inc.. President and CEO Dr. Soren Mogelsvang states, “This is a milestone event in the very short timeline since the inception of our Company. Not only are we generating revenues, but we are also capturing exceptional business intelligence as regards the marketing, sales and distribution of hemp based and CBD enhanced products. To-date, our industry is in its infancy and relatively uncharted, which led us to determine that initiating commercial activities within the recession-proof pet health sector would offer extraordinary promise for growth within the shortest possible timeframe. Insofar as we remain firmly focused on the development of human therapies, we believe Canna-Pet™ offers sustainable and predictable growth while offering a profoundly gratifying service to our customers, and is already well on the way to achieving an excellent projected return on our investment in as little as 6 months based on all early indications.”

Quelle: http://peakpharma.com/cannabis-therapy-corp-announces-revenu…

[clickclickcash]

Peak Pharmaceuticals, Inc. Announces Name Change From Cannabis Therapy Corp.

January 13, 2015

Corporate Business Plan Remains Focused on Development, Sales and Marketing of Hemp-Based Supplements and Medicinal Products

BOULDER, CO–Peak Pharmaceuticals, Inc. (OTCQB: CTCO), formerly Cannabis Therapy Corp. (the “Company”), a growth stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, hemp-based medicinal therapies and supplements (Nutraceuticals), wishes to advise that on December 23, 2014, Cannabis Therapy Corp., a Nevada corporation, entered into an Agreement and Plan of Merger pursuant to which the shareholders of the Company became shareholders of the surviving company named Peak Pharmaceuticals, Inc., a Nevada corporation.

The Company’s common stock will temporarily remain listed for quotation on OTC Markets under the current symbol “CTCO” until a new symbol is assigned by Financial Industry Regulatory Authority, Inc. (FINRA). The Company will publicly announce the new trading symbol when assigned by FINRA and the effective date of the symbol change.

Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang states, “The name change was made to make our name more consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based, pharmaceutical-grade, nutraceutical and supplement products for the human and animal health markets.”

Quelle: http://peakpharma.com/peak-pharmaceuticals-inc-announces-nam…" target="_blank" rel="nofollow ugc noopener">http://peakpharma.com/peak-pharmaceuticals-inc-announces-nam…

[clickclickcash]

Peak Pharmaceuticals Is Pleased to Announce Strong Order Volume for Its Canna-Pet Products

January 15, 2015

BOULDER, CO–Peak Pharmaceuticals, Inc. (OTCQB: CTCO) (“Peak Pharma” or the “Company”), a growth stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, hemp-based, medicinal therapies and supplements (Nutraceuticals) for both humans and animals is pleased to advise of recent corporate achievements.

The Company is extremely pleased to announce that since processing the first Canna-Pet™ order on October 16, 2014, the company has processed and shipped more than 3,000 orders, exceeding internal forecasts for product sales. The Canna-Pet™ products are available under a worldwide, exclusive licensing agreement held by Peak Pharmaceuticals, and are sold online (www.canna-pet.com) as well as through select veterinary clinics.

Additionally, the Company recently signed a lease for office and laboratory space at the BioScience Park Center which is located on the Anschutz Medical Campus at the University of Colorado, Denver. The laboratory is designed to establish a series of inflammatory assays and models with the goal of enabling the identification and characterization of hemp strains and extract types for the development of nutraceutical and supplement products aimed at the human health market. The company also aims to turn its own hemp crop, cultivated during 2014, into product prototypes for testing, production, and ultimately groundbreaking first-to-market retail products.

In related news, Company CEO Dr. Soren Mogelsvang has recently joined with the Rocky Mountain Hemp Association (http://rockymountainhempassociation.org/content) in a collaborative capacity aimed at offering insights into the areas of medicinal product development and commercialization with this rapidly growing group of regional industry stakeholders.

“We have been extremely busy as we continue to build momentum on a number of fronts in this fast paced industry,” states Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang, who continues, “Launching into the companion animal sector has been a big and exciting opportunity for us. Our sales have been excellent and it’s really gratifying to work with a consumer audience that is passionate about the product. We are very aware that the Pet Supplies market segment, which includes products such as our Canna-Pet product line-up, totaled $14 billion in 2013 and that 41% of pet owners have considered or tried various alternative therapies. That’s huge. On the human side, the Global Nutraceutical Market is projected to reach $207 billion by 2016. Together, these numbers highlight that even a small market share would represent significant, sustainable and increasing revenues for our growing Company.”

Quelle: http://peakpharma.com/peak-pharmaceuticals-pleased-announce-…

[clickclickcash]

barchart.com Opinion as of Fri, Jan 16th, 2015

Short Term Indicators Average: 60% Buy
Medium Term Indicators Average: 25% Buy
Long Term Indicators Average: 67% Sell
Overall Average: 16% Buy

Quelle: http://www.barchart.com/opinions/stocks/CTCO

barchart.com Snapshoot Opinion
http://www.barchart.com/snapopinion/stocks/CTCO

[VanGillen]

Quelle:yahoo.
Spitzen Pharmaceuticals, Inc., über ihre Tochtergesellschaft, Berggipfel BioPharma Corp., engagiert sich in der Entwicklung, Herstellung und Vermarktung von Hanf-basierten Nahrungsergänzungsmittel und Ergänzungsprodukte für die menschliche und tierische Gesundheit Märkten. Das Unternehmen ist in der Herstellung und dem Verkauf von Hanf orientierte Tiergesundheitsprodukte auf Basis von Canna-Haustier-Lizenzvereinbarung beteiligt. Sie beabsichtigt, over-the-counter, ultra-low und tetrahydrocannabinoil frei und Hanf-basierte Produkte zur Vorbeugung und Linderung von entzündlichen und Autoimmunerkrankungen zu entwickeln. Das Unternehmen wurde früher als Cannabis-Therapie Gesellschaft bekannt und änderte ihren Namen in Spitzen Pharmaceuticals, Inc. im Dezember 2014. Das Unternehmen befindet sich in Aurora, Colorado.

Da läßt sich doch bestimmt das Herrchen was ordentliches verschreiben.
Da wird so manch Vierbeiner plötzlich zum Zweibeiner.

[clickclickcash]

Antwort auf Beitrag Nr.: 48.817.331 von VanGillen am 19.01.15 12:03:22

Interessant ist die steigende Nachfrage bzw. die steigende Anzahl von Aufträgen für dieses Canna-Pet Produkt.

Gepaart mit dem wieder aufgeflammten Hype um die "Potstocks" wie $CANN, $CANV und auch Deutsche Cannabis AG.

Ps.: Amüsante Übersetzung

[clickclickcash]

+ 130% !!!
...und das ohne Handel in den USA.
Morgen geht's erst richtig rund...

[clickclickcash]

This Is Where The Investment Opportunity Is Right Now In Cannabis

Jan. 20, 2015 12:25 PM ET | Includes: $CTCO, $GWPH, $INSY, $OXIS

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Summary
•Marijuana stocks have been incredibly volatile since the cannabis revolution began in 2014.

•Until 2016, new state legislation will be hard to come by, which will be more of a burden to those companies solely focused on recreational or retail based marijuana sales.

•In the cannabis sector, investors are finding more opportunity with stocks with companies that focus on the biotech space with products in the pipeline for FDA approval Vs state approval.

•Biotech historically has shown a more consistent growth pattern comparatively speaking.



Long has been the stigma that marijuana stocks are something to be leery of especially with how many portfolios have been riddled with losses during the midst of the marijuana blitz. Analyzing the industry as a whole and looking back at the first year in history where marijuana has been legal, we can really study what the good investments were and what trades were not so profitable.

With such a burgeoning space there is way more "noise" that can affect the success of companies involved within this space. These include local business chambers of commerce, political opposition, and federal regulation, but one aspect that flies under the radar, so to speak, has been involvement within biotech and pharmaceuticals. Furthermore, hemp's legal status has made it an attractive target for companies looking to steer clear of the conflicting U.S. law that surrounds the medical cannabis industry.

Look at a company like GW Pharmaceuticals (NASDAQ:GWPH). This is a British based biopharmaceutical company, which has become well-known for its novel approach to pharmaceutical therapy. The company's multiple sclerosis treatment product, Sativex, (nabiximols) is the first natural cannabis plant derivative to gain full market approval in any country. Over the last 18 months during the "dawn of marijuana legalization", this was one of the stocks to watch. Share prices skyrocketed to highs of over $110 per share all while the company continued to make announcements on successful clinical trials

Since hitting those highs, GW's stock price has pulled back but not to a point of crumbling. The company's recent update on its development program for Epidiolex(NYSE:R) in the field of severe, drug-resistant childhood epilepsy sparked a strong surge in momentum. The update was made in conjunction with the company's announcement on the results from its first of three Phase 3 trials for the investigational product Sativex in "the treatment of pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy".

January 8 was when these announcements were released and on that day alone the stock price jumped 18% from open to high and reached a level above $80/share. This is a price that GWPH shares have not seen since late November and marked the first time that the stock showed signs of reversing from the previous downtrend just prior to the close of 2014. Furthermore, GWPH could be looking at a bull-flag pattern, setting up for a possible break to higher levels. As you'll see with these additional cannabis biotechs, the entire sector seems to be lifting right now.

Currently GW Pharma shows that its burn rate from operations is roughly $1.7M/mo. This is significantly higher from prior years and a potential point of risk for GW. Being that the company is very dependent on its single product, Sativex, investors should be aware that though this is a larger market cap company in the cannabis space, there are regulatory approvals that will still need to be met by the FDA in the US.

This leads me to INSYS Therapeutics, Inc. (NASDAQ:INSY). Monday morning, the company announced progress and "expected milestones" for multiple projects in its pipeline of supportive care and therapy products & candidates. For this company, Insys focuses on a sublingual spray as a delivery method and is moving forward with research and trials for pharmaceutical cannabinoids both for pain therapy in cancer patients as well as treatment for pediatric epilepsy. The company has already submitted an Investigational New Drug application for the pharmaceutical cannabidiol formulation for the treatment of epilepsy.

In a recent press release, the company focused on development in 2015 citing that it will be conducting Phase III studies for its buprenorphine sublingual spray for the treatment of acute pain and expects to complete this by 2016. Additionally, Insys has recorded positive outcomes of its Phase I study of its sublingual spray buprenorphine/naloxone candidate as well as filing an Investigational New Drug application for its ondansetron sublingual spray candidate, expecting it to complete a pilot pharmacokinetic study in the first quarter of 2015.

This mix of positive news, new studies in the pipeline and positive results from its most recent quarterly filing have helped to propel the stock to new highs and continue the latest bull-run. The results include a 90.7% Gross Margin, a 99% increase in net revenues from the same quarter 2013 by nearly $30M, and an increase in net cash provided by operating activities by $20M for the nine month period ending Sept. 30 compared to the previous period in 2013. INSY operates very lean as evidenced by the cost of revenue being only about 1% of the total Gross revs.

Even if the company remains constant with its operations and reports an average of $10m in net income per quarter, INSY operates at roughly 39x earnings. Furthermore, the company operates fairly lean. In line with this, the share price has remained on an upward trend since May of last year. After churning between $22-$24 per share for nearly the entire summer, INSY made an about face and hasn't looked back ever since. As of this report, the stock has managed highs of $49 as of Jan 14, 2015 and doesn't show many signs of pull-back.

As hemp gains more popularity for a source of CBDs, its legal status has made it a very appealing target for companies looking to avoid the U.S. law that surrounds the medical cannabis industry. For instance, in 2004, the U.S. Supreme Court ruled in HIA v. DEA that hemp would be legal to cultivate and process for sale "as a food or beverage in the United States". The 2014 U.S. Farm Bill permitted cultivation of domestic hemp in states like Colorado on a limited basis and just recently Senate Bill 134, to "legalize industrial hemp cultivation and production", was filed and assigned to a Congressional committee on Thursday, January 8, 2015 by Senator Ron Wyden (D-OR) and co-sponsored by Senator McConnell (D-OR), Senator Merkley (D-OR), and, Senator Rand Paul (R-KY). The bill titled "Industrial Hemp Farming Act of 2015" would "remove federal restrictions on the domestic cultivation of industrial hemp."

In both cases (Farm Bill & Industrial Farming Act) the approval of these new bills could make 2015 a banner year for new innovation within the biotech space especially for companies focused on extracting the benefits from hemp. The reason for this is because up until recently, companies manufacturing hemp-based products were forced to import the raw material. Aside from GW Pharma and Insys, other companies are also coming on board and adopting a more biotechnology focused approach to the market opportunity in this burgeoning cannabis space.

Take a company like PEAK Pharmaceuticals Inc. (previous, Cannabis Therapy Corp) (OTCQB:CTCO), which has received increased market attention following its name change and recent focus on the animal markets. Recently the company signed a worldwide license agreement with Canna-Pet LLC and a cultivation agreement with a Colorado-based hemp farm. This should bode well for PEAK not only for opportunity for growth in the medical cannabis space but also in the pet markets as well. According to the American Pet Products Association, the U.S. pet industry has grown at an 8% CAGR to reach $58.51 billion by 2014.

Thursday the company announced favorable sales results for its Canna-Pet product. According to PEAK, the company has processed and shipped more than 3,000 orders. A mix of news and financials that hold over $4m in paid in capital, should appeal to new investors as the company itself has such a vested interest in continued progress within the CBD space.

Net cash used in operating activities was $933,475 for the year ended September 30, 2014, as compared to net cash used of $15,567 for the year ended September 30, 2013. According to the company, this increase in net cash used in operations was primarily due to the change in operating plans. Note that share price, market volatility and posting a net loss for the year of $3,758,815 are all very important risks to be aware of when looking at Peak as a potential investment option in the biopharma/cannabis market.

Oxis International, Inc. (OTCPK:OXIS) (OXI.PA) through its subsidiary, Oxis Biotech, Inc. has recently come into the space as well. It appears that following the company becoming current with its filings as well as releasing two very prominent pieces of press, activity in the stock has increased with January 14 seeing the highest volume day in the stock. Over the last 30 days, Oxis shares also have seen highs of $0.039 even with the caveat status on OTC Markets. This was an obvious trigger to take a closer look as seemingly, "something's up".

Over recent weeks, the company has made two announcements that put this on the list of possible cannabis investments in 2015 and both are material in nature. Further diligence shows that not only has Oxis executed definitive agreements licensing certain assets for the treatment of multiple myeloma but the company has also brought on one of the foremost authorities in CBD research especially those diagnosed with multiple myeloma, breast cancer, and even research in the stem cell arena, Dr. Sean Xie (Dr. Xiangqun Xie). According to the website cbdligand.org, "Xie's research work is beyond the proof-of-principle stage since his group has already successfully identified several novel CB2 ligands with nanomolar receptor binding affinity (US patents). The methods and results developed will have a significant impact on the other GPCRs drug research in general. Currently, he has established collaboration with MD experts in University of Pittsburgh Medical Center for in vivo animal evaluation."

In addition to this, the Company also announced that Dr. James J. Mulé, Ph.D. who is a Special Government Employee of the NCI and the FDA, joins that company's Scientific Advisory Board. Among many of his accomplishments, Dr. Mulé is recognized for his translational research studies in cancer immunotherapy. Mulé previously worked with Oxis CEO Tony Cataldo when Mr. Cataldo previously formed Genesis Biopharma (previous GNBP) which later became Lion Biotechnologies. Under the helm of Mr. Cataldo, Genesis came from a penny stock and built enough shareholder value to increase to $8+ per share.

As far as paid in capital is concerned, Oxis shows more of a vested interest along the lines of a company like Insys as opposed to one like PEAK. Therefore it could be very possible that the CEO who took Genesis to "the next level" may have found another company to build as OXIS has continued to gain more investor interest this past week. Despite these achievements and increased market liquidity, the obvious risks unassociated with the small market cap, lower share price, and volatility will also include the fact that Oxis will still need to put in place a plan or outline for what the company will focus on specifically. A strong team to conduct R&D is a good start but as the company has just become fully reporting, the need for more company developments regarding production is needed in my opinion.

As noted in several instances, I've mentioned paid in capital in this article for the simple fact that many biotechs generally are pre-revenue through the multiple stages of R & D and phases of FDA approval. This valuation method has been used because when you're not selling product, how can success be determined? By utilizing "paid-in-capital" valuations, investors can clearly see that amount of capital available to fund a biotech company's research.

Investing in cannabis companies in the US at this point remains highly speculative and obvious risks reach far beyond simple market volatility. As far as biotechs go, drugs not passing FDA approval or even reacting negatively during the trial periods can put a huge barrier up for a company. For the cannabis industry as a whole (even though it doesn't necessarily effect biotechs) federal regulation can change at any point and time so just as the government made certain aspects legal, they can easily overturn those to make them illegal. The main point is that by investing in reputable companies focused on biotech may produce significant returns in the current climate as many states have not legalized the drug for over the counter sale.

The real investment right now I feel is in the biotech side of the space. For one, as far as regulatory issues are concerned, these companies do not face the same state-by-state restrictions that many typical marijuana based businesses face. Much of the studies are funded by government-sponsored funds and thus would have to meet the criteria of organizations like the FDA. This makes biotech a great candidate through 2016, which is when the next elections are planned & potential legalization votes go back on the ballot. Second, the biotech space is growing at an annual rate of 11% (market revenue is just under $300B according to IBISWorld). Finally, The Arcview Group forecasts that the legal marijuana industry will increase to $10 billion in 2019, so there is obvious opportunity within the industry just as it is beginning to grow. As history has proven with growth driven industries, the first-movers who take an early foothold manage to gain the largest market share. What companies like Google and Apple have done for tech, cannabis biotechs like those mentioned can do it for the marijuana industry.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Quelle: http://seekingalpha.com/article/2833006-this-is-where-the-in…

[clickclickcash]

Cannabis News

- Peak Pharmaceuticals Lays Out Plan to Drive Value in 2015 - Peak Pharmaceuticals Inc. (OTC:CTCO) recently announced its plans to generate long-term shareholder value in 2015 while recapping its accomplishments in 2014.

- Peak Pharmaceuticals Sees Strong Demand for Canna-Pet Products - Peak Pharmaceuticals Inc. (OTC:CTCO) reported strong demand for its Canna-Pet products that provide the potential beneficial effects of CBDs to pets.

http://www.barchart.com/headlines/story/5094691/cannabisfn-w…

[clickclickcash]

Peak Pharmaceuticals Develops Market Entry Strategy and Plan Aided by Outstanding Executive MBA Teams

Company Benefits From In-Depth Study and Embarks on Three Year Plan to Gain Market Share

January 21, 2015

Peak Pharmaceuticals, Inc. (OTCQB: CTCO) ("Peak Pharma" or the "Company"), a growth stage company aiming to become a leader in the research, development, sales and marketing of safe, all-natural, hemp-based, medicinal therapies and supplements (Nutraceuticals) for both humans and animals is pleased to advise that it has recently completed an in-depth analysis of the human and veterinary supplement markets, and the development of a three year market entry strategy. The project was done through a strategic academic collaboration.

Working under the auspices of the 2014 Executive Multidisciplinary Action Program at the Stephen M. Ross School of Business at the University of Michigan, two teams of Executive MBA (EMBA) students were engaged in September, 2014 to carry out a three month project in close collaboration with Peak Pharmaceuticals as industry partner. The research included a detailed analysis of the nutraceutical sector and preparation of three-year market entry strategies for hemp-based products targeting human and animal health channel markets.

The project scope included assessment and situational analysis of the target market domains including customer segments and channels, an in depth study of the competitive landscape, and a strategy for aggressively entering these markets.

Both EMBA teams delivered their final reports in December, including executive summaries, as well as base case product launch strategies along with a detailed analysis of the company, competitors, customers, collaborators and context (5C's) across the U.S. nutraceutical/medical hemp market. Additional details included an analysis of segmentation, targeting and positioning, pricing policies, route to market and gaps within current strategies.

The deliverables further included (where applicable) survey results of key interviewees from relevant industries and consumer groups, and culminated with a 3-year plan for proposed activities with potential extended "blue sky" strategies.

Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang states, "We were thrilled and gratified by the opportunity to work with the very enthusiastic and professional executives that comprised our two teams. Through this relationship with the Stephen M. Ross School of Business at the University of Michigan, we gained access to invaluable resources, typically beyond the reach of smaller companies such as ours. We are really pleased to have such well-researched and detailed 'roadmaps' for our ongoing business development activities, aiding both our Canna-Pet™ sales and, perhaps more importantly, with our future aims for human CBD products. This will undoubtedly save tens of thousands of dollars down the road and accelerate our market entry. The information at hand is far more in-depth than pretty much any business plan I've ever seen before, and it will serve us very well as we continue to build Peak Pharma into a profitable and sustainable nutraceutical company. I'd like to personally thank the leadership at the Ross School and again offer my heartfelt thanks to both teams for an excellent and well done job."

Quelle: http://money.cnn.com/news/newsfeeds/articles/marketwire/1170…

[clickclickcash]

SeeThruEquity Initiates Coverage on Peak Pharmaceuticals $CTCO with Price Target of $1.26

Quelle: http://yhoo.it/15OW8bJ

[clickclickcash]

Peak Pharma Inc. is looking for participants to complete a nationwide survey investigating the use of CBD-based products for animals.
http://tiny.cc/byuhtx